Observational studyJournal of gastrointestinal cancer2025
Prehabilitation Targets Associated with the Omission of Adjuvant Chemotherapy After Surgery for Pancreatic Cancer.
Observational study in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCurative treatment for pancreatic cancer relies on surgical resection combined with systemic chemotherapy, administered either before (neoadjuvant) or after (adjuvant) surgery. However, a considerable proportion of patients undergoing upfront resection fail to receive adjuvant chemotherapy, which negatively impacts survival. Identifying modifiable preoperative factors contributing to this omission could improve postoperative outcomes. This study investigated potential prehabilitation targets associated with the omission of adjuvant chemotherapy following pancreatic cancer surgery.
methodsWe conducted a post-hoc analysis of a prospective observational cohort including all patients who underwent pancreaticoduodenectomy at the Regional Academic Cancer Centre Utrecht between 2016 and 2022. The primary outcome was omission of adjuvant chemotherapy. Associations between prehabilitation-related factors-smoking, alcohol use, nutritional status, anemia, mobility, muscle strength, mental stress, and exocrine pancreatic insufficiency-were assessed using logistic regression. As a secondary analysis, we examined the relationship between these factors and major postoperative complications, a known determinant of chemotherapy omission.
resultsIn total, 214 patients were included of which 115 patients (54%) were male with a median age of 70 years (± 7 years). A total of 70/214 patients (33%) did not start with adjuvant chemotherapy. Only smoking was independently associated with omitting chemotherapy (adjusted odds ratio (aOR) 2.98, 95% confidence interval (CI) 1.25-7.13, P < 0.01). Patients who suffered from major postoperative complications were less likely to receive adjuvant chemotherapy (aOR 2.36, 95%CI 1.07-5.18, P = 0.03). Again, only smoking was associated with a major postoperative complication (aOR 2.27, 95% CI 1.08-4.76).
conclusionSmoking is a modifiable prehabilitation target linked to both omission of adjuvant chemotherapy and increased risk of major postoperative complications following pancreatic surgery.
Indexed as
Identifiers
41288854What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.